Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-guided multi-agent chemotherapy for first relapsed or refractory childhood acute lymphoblastic leukemia
ACTRN12608000495325Phase 3Completed
- Sponsor
- University Hospitals of Leicester NHS Trust
- Start
- Nov 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of methotrexate, idarubicin, mitoxantrone, dexamethasone, vincristine and 5 more in acute lymphoblastic leukemia (ALL), sponsored by University Hospitals of Leicester NHS Trust. Primary endpoints: Progression-free survival for all patients stratified by risk group and Progression-free survival. Started Nov 2006; status: completed.
02
Drugs
methotrexateidarubicinmitoxantronedexamethasonevincristine
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ACTRN12608000495325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000495325.